IL-22, cell regeneration and autoimmunity

Cytokine

Volumn 74, Issue 1, 2015, Pages 35-42

  Nikoopour, Enayat ^a   Bellemore, Stacey M ^a   Singh, Bhagirath ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Aryl hydrocarbon receptor (AhR); Autoimmune diseases; IL 22; IL 23; Regenerating (Reg) genes

Indexed keywords

INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; AROMATIC HYDROCARBON RECEPTOR; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; RETINOID RELATED ORPHAN RECEPTOR GAMMA;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BINDING AFFINITY; BINDING SITE; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; HUMAN; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; EPITHELIUM CELL; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; REGENERATION;

ANIMALS; AUTOIMMUNITY; CELL DIFFERENTIATION; CYTOKINES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; MICE; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; RECEPTORS, ARYL HYDROCARBON; REGENERATION; TH17 CELLS;

EID: 84930182650     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.09.007     Document Type: Review

References (129)

1. Dumoutier L., Louahed J., Renauld J.C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000, 164:1814-1819.
2. Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z., Stinson J., et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000, 275:31335-31339.
3. Dumoutier L., Van R.E., Ameye G., Michaux L., Renauld J.C. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun 2000, 1:488-494.
4. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011, 12:383-390.
5. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
6. Vivier E., Spits H., Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair?. Nat Rev Immunol 2009, 9:229-234.
7. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
8. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011, 12:21-27.
9. Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011, 29:71-109.
10. Lee J.S., Cella M., Colonna M. AHR and the transcriptional regulation of type-17/22 ILC. Front Immunol 2012, 3:10.
11. Qiu J., Heller J.J., Guo X., Chen Z.M., Fish K., Fu Y.X., et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012, 36:92-104.
12. Sciume G., Hirahara K., Takahashi H., Laurence A., Villarino A.V., Singleton K.L., et al. Distinct requirements for T-bet in gut innate lymphoid cells. J Exp Med 2012, 209:2331-2338.
13. Kim S., Han S., Withers D.R., Gaspal F., Bae J., Baik S., et al. CD117(+) CD3(-) CD56(-) OX40Lhigh cells express IL-22 and display an LTi phenotype in human secondary lymphoid tissues. Eur J Immunol 2011, 41:1563-1572.
14. Takatori H., Kanno Y., Watford W.T., Tato C.M., Weiss G., Ivanov I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009, 206:35-41.
15. Eberl G., Littman D.R. The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer's patches. Immunol Rev 2003, 195:81-90.
16. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001, 276:2725-2732.
17. de Oliveira N.M., Ferreira J.R., Colau D., Fischer H., Nascimento A.S., Craievich A.F., et al. Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys J 2008, 94:1754-1765.
18. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002, 277:33676-33682.
19. Gurney A.L. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 2004, 4:669-677.
20. Tachiiri A., Imamura R., Wang Y., Fukui M., Umemura M., Suda T. Genomic structure and inducible expression of the IL-22 receptor alpha chain in mice. Genes Immun 2003, 4:153-159.
21. Whittington H.A., Armstrong L., Uppington K.M., Millar A.B. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 2004, 31:220-226.
22. Aggarwal S., Xie M.H., Maruoka M., Foster J., Gurney A.L. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 2001, 21:1047-1053.
23. Shioya M., Andoh A., Kakinoki S., Nishida A., Fujiyama Y. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas 2008, 36:197-199.
24. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 2001, 166:7096-7103.
25. Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S., Chen Z., et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A 2001, 98:9511-9516.
26. Dumoutier L., Lejeune D., Colau D., Renauld J.C. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001, 166:7090-7095.
27. Huber S., Gagliani N., Zenewicz L.A., Huber F.J., Bosurgi L., Hu B., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
28. Radaeva S., Sun R., Pan H.N., Hong F., Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004, 39:1332-1342.
29. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010, 207:1293-1305.
30. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
31. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647-659.
32. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119:3573-3585.
33. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Stevens S., Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
34. Baeza N., Sanchez D., Vialettes B., Figarella C. Specific reg II gene overexpression in the non-obese diabetic mouse pancreas during active diabetogenesis. FEBS Lett 1997, 416:364-368.
35. Liu L., Liu J.L., Srikant C.B. Reg2 protects mouse insulinoma cells from streptozotocin-induced mitochondrial disruption and apoptosis. Growth Factors 2010, 28:370-378.
36. Xiong X., Wang X., Li B., Chowdhury S., Lu Y., Srikant C.B., et al. Pancreatic islet-specific overexpression of Reg3beta protein induced the expression of pro-islet genes and protected the mice against streptozotocin-induced diabetes mellitus. Am J Physiol Endocrinol Metab 2011, 300:E669-E680.
37. Huszarik K., Wright B., Keller C., Nikoopour E., Krougly O., Lee-Chan E., et al. Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice. J Immunol 2010, 185:5120-5129.
38. Liu J.L., Cui W., Li B., Lu Y. Possible roles of reg family proteins in pancreatic islet cell growth. Endocr Metab Immune Disord Drug Targets 2008, 8:1-10.
39. Parikh A., Stephan A.F., Tzanakakis E.S. Regenerating proteins and their expression, regulation and signaling. Biomol Concepts 2012, 3:57-70.
40. Unno M., Nata K., Noguchi N., Narushima Y., Akiyama T., Ikeda T., et al. Production and characterization of Reg knockout mice: reduced proliferation of pancreatic beta-cells in Reg knockout mice. Diabetes 2002, 51(Suppl 3):S478-S483.
41. Qin H.Y., Sadelain M.W., Hitchon C., Lauzon J., Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol 1993, 150:2072-2080.
42. Sadelain M.W., Qin H.Y., Lauzon J., Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990, 39:583-589.
43. Nikoopour E., Schwartz J.A., Huszarik K., Sandrock C., Krougly O., Lee-Chan E., et al. Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. J Immunol 2010, 184:4779-4788.
44. Hill T., Krougly O., Nikoopour E., Bellmore S., Lee-Chan E., Fouser L.A., et al. The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes. Cell Regen 2013, 2:1-11.
45. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14:275-281.
46. Dudakov J.A., Hanash A.M., Jenq R.R., Young L.F., Ghosh A., Singer N.V., et al. Interleukin-22 drives endogenous thymic regeneration in mice. Science 2012, 336:91-95.
47. Abe H., Kimura A., Tsuruta S., Fukaya T., Sakaguchi R., Morita R., et al. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN-gamma expression and inducing IL-22. Int Immunol 2014, 26:129-137.
48. Xue J., Nguyen D.T., Habtezion A. Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis. Gastroenterology 2012, 143:1670-1680.
49. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
50. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006, 36:1309-1323.
51. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008, 14:282-289.
52. De L.A., Zelante T., D'Angelo C., Zagarella S., Fallarino F., Spreca A., et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010, 3:361-373.
53. Guo X., Qiu J., Tu T., Yang X., Deng L., Anders R.A., et al. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity 2014, 40:25-39.
54. Sonnenberg G.F., Monticelli L.A., Elloso M.M., Fouser L.A., Artis D. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 2011, 34:122-134.
55. Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
56. Longman R.S., Diehl G.E., Victorio D.A., Huh J.R., Galan C., Miraldi E.R., et al. CX3CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med 2014.
57. Satpathy A.T., Briseno C.G., Lee J.S., Ng D., Manieri N.A., Kc W., et al. Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol 2013, 14:937-948.
58. Korn L.L., Thomas H.L., Hubbeling H.G., Spencer S.P., Sinha R., Simkins H.M., et al. Conventional CD4+ T cells regulate IL-22-producing intestinal innate lymphoid cells. Mucosal Immunol 2014.
59. Liang S.C., Nickerson-Nutter C., Pittman D.D., Carrier Y., Goodwin D.G., Shields K.M., et al. IL-22 induces an acute-phase response. J Immunol 2010, 185:5531-5538.
60. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
61. Zenewicz L.A., Yin X., Wang G., Elinav E., Hao L., Zhao L., et al. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol 2013, 190:5306-5312.
62. Sanos S.L., Bui V.L., Mortha A., Oberle K., Heners C., Johner C., et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol 2009, 10:83-91.
63. Behnsen J., Jellbauer S., Wong C.P., Edwards R.A., George M.D., Ouyang W., et al. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity 2014, 40:262-273.
64. Munoz M., Heimesaat M.M., Danker K., Struck D., Lohmann U., Plickert R., et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009, 206:3047-3059.
65. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
66. Esplugues E., Huber S., Gagliani N., Hauser A.E., Town T., Wan Y.Y., et al. Control of TH17 cells occurs in the small intestine. Nature 2011, 475:514-518.
67. Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467:967-971.
68. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
69. Singh B., Schwartz J.A., Sandrock C., Bellemore S.M., Nikoopour E. Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Indian J Med Res 2013, 138:591-594.
70. Rutz S., Noubade R., Eidenschenk C., Ota N., Zeng W., Zheng Y., et al. Transcription factor c-Maf mediates the TGF-beta-dependent suppression of IL-22 production in T(H)17 cells. Nat Immunol 2011, 12:1238-1245.
71. Xu J., Yang Y., Qiu G., Lal G., Wu Z., Levy D.E., et al. C-Maf regulates IL-10 expression during Th17 polarization. J Immunol 2009, 182:6226-6236.
72. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863.
73. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109.
74. Veldhoen M., Hirota K., Christensen J., O'Garra A., Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009, 206:43-49.
75. Pot C., Jin H., Awasthi A., Liu S.M., Lai C.Y., Madan R., et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 2009, 183:797-801.
76. Duarte J.H., Di M.P., Hirota K., Ahlfors H., Stockinger B. Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLoS One 2013, 8:e79819.
77. Di M.P., Duarte J.H., Ahlfors H., Owens N.D., Li Y., Villanova F., et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 2014, 40:989-1001.
78. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
79. Quintana F.J., Murugaiyan G., Farez M.F., Mitsdoerffer M., Tukpah A.M., Burns E.J., et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010, 107:20768-20773.
80. Yeste A., Mascanfroni I.D., Nadeau M., Burns E.J., Tukpah A.M., Santiago A., et al. IL-21 induces IL-22 production in CD4+ T cells. Nat Commun 2014, 5:3753.
81. Apetoh L., Quintana F.J., Pot C., Joller N., Xiao S., Kumar D., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010, 11:854-861.
82. Qiu J., Guo X., Chen Z.M., He L., Sonnenberg G.F., Artis D., et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 2013, 39:386-399.
83. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
84. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
85. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
86. Yang X.O., Panopoulos A.D., Nurieva R., Chang S.H., Wang D., Watowich S.S., et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007, 282:9358-9363.
87. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
88. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
89. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002, 110:493-497.
90. Schmidt C., Giese T., Ludwig B., Mueller-Molaian I., Marth T., Zeuzem S., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005, 11:16-23.
91. Elson C.O., Cong Y., Weaver C.T., Schoeb T.R., McClanahan T.K., Fick R.B., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132:2359-2370.
92. Izcue A., Hue S., Buonocore S., Rancibia-Carcamo C.V., Ahern P.P., Iwakura Y., et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008, 28:559-570.
93. Mizuno S., Mikami Y., Kamada N., Handa T., Hayashi A., Sato T., et al. Cross-talk between RORgammat+ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease. Inflamm Bowel Dis 2014, 20:1426-1434.
94. Monteleone I., Rizzo A., Sarra M., Sica G., Sileri P., Biancone L., et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011, 141:237-248.
95. Hanash A.M., Dudakov J.A., Hua G., O'Connor M.H., Young L.F., Singer N.V., et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37:339-350.
96. Hue S., Ahern P., Buonocore S., Kullberg M.C., Cua D.J., McKenzie B.S., et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006, 203:2473-2483.
97. Kullberg M.C., Jankovic D., Feng C.G., Hue S., Gorelick P.L., McKenzie B.S., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006, 203:2485-2494.
98. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
99. Buonocore S., Ahern P.P., Uhlig H.H., Ivanov I.I., Littman D.R., Maloy K.J., et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010, 464:1371-1375.
100. Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013, 210:917-931.
101. Eken A., Singh A.K., Treuting P.M., Oukka M. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol 2014, 7:143-154.
102. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006, 116:1317-1326.
103. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175.
104. Kreymborg K., Etzensperger R., Dumoutier L., Haak S., Rebollo A., Buch T., et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179:8098-8104.
105. Joseph J., Bittner S., Kaiser F.M., Wiendl H., Kissler S. IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. J Immunol 2012, 188:216-221.
106. Ishigame H., Zenewicz L.A., Sanjabi S., Licona-Limon P., Nakayama M., Leonard W.J., et al. Excessive Th1 responses due to the absence of TGF-beta signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci USA 2013, 110:6961-6966.
107. Bending D., De La P.H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009, 119:565-572.
108. Martin-Orozco N., Chung Y., Chang S.H., Wang Y.H., Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009, 39:216-224.
109. Nurieva R., Yang X.O., Chung Y., Dong C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol 2009, 182:2565-2568.
110. Kerkvliet N.I., Steppan L.B., Vorachek W., Oda S., Farrer D., Wong C.P., et al. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 2009, 1:539-547.
111. Wolk K., Haugen H.S., Xu W., Witte E., Waggie K., Anderson M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 2009, 87:523-536.
112. Piskin G., Sylva-Steenland R.M., Bos J.D., Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176:1908-1915.
113. Res P.C., Piskin G., de Boer O.J., van der Loos C.M., Teeling P., Bos J.D., et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010, 5:e14108.
114. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
115. Pene J., Chevalier S., Preisser L., Venereau E., Guilleux M.H., Ghannam S., et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008, 180:7423-7430.
116. Boniface K., Guignouard E., Pedretti N., Garcia M., Delwail A., Bernard F.X., et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007, 150:407-415.
117. Van Belle A.B., de H.M., Lemaire M.M., Hendrickx E., Warnier G., Dunussi-Joannopoulos K., et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 2012, 188:462-469.
118. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.
119. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
120. Cornelissen F., Asmawidjaja P.S., Mus A.M., Corneth O., Kikly K., Lubberts E. IL-23 dependent and independent stages of experimental arthritis: no clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis. PLoS One 2013, 8:e57553.
121. van Hamburg J.P., Corneth O.B., Paulissen S.M., Davelaar N., Asmawidjaja P.S., Mus A.M., et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013, 72:1700-1707.
122. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037-1046.
123. Geboes L., Dumoutier L., Kelchtermans H., Schurgers E., Mitera T., Renauld J.C., et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60:390-395.
124. Carrion M., Juarranz Y., Seoane I.V., Martinez C., Gonzalez-Alvaro I., Pablos J.L., et al. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction. J Mol Neurosci 2014, 52:10-17.
125. Justa S., Zhou X., Sarkar S. Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-gamma responses. PLoS One 2014, 9:e93279.
126. Sarkar S., Zhou X., Justa S., Bommireddy S.R. Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum 2013, 65:960-971.
127. Pineda M.A., Rodgers D.T., Al-Riyami L., Harnett W., Harnett M.M. ES-62 protects against collagen-induced arthritis by resetting interleukin-22 toward resolution of inflammation in the joints. Arthritis Rheumatol 2014, 66:1492-1503.
128. O'Donnell E.F., Saili K.S., Koch D.C., Kopparapu P.R., Farrer D., Bisson W.H., et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One 2010, 5.
129. Nakahama T., Kimura A., Nguyen N.T., Chinen I., Hanieh H., Nohara K., et al. Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. Proc Natl Acad Sci USA 2011, 108:14222-14227.